| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study ☆
|
Passaro, A.
|
|
|
35 |
1 |
p. 77-90
|
artikel
|
| 2 |
Annals of Oncology – passing the baton, raising the bar
|
Powles, Thomas
|
|
|
35 |
1 |
p. 3
|
artikel
|
| 3 |
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
|
Prelaj, A.
|
|
|
35 |
1 |
p. 29-65
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
35 |
1 |
p. iii
|
artikel
|
| 5 |
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
|
Catto, J.W.F.
|
|
|
35 |
1 |
p. 98-106
|
artikel
|
| 6 |
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial ☆
|
Siefker-Radtke, A.O.
|
|
|
35 |
1 |
p. 107-117
|
artikel
|
| 7 |
Erratum to “Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project”
|
Vega, D.M.
|
|
|
35 |
1 |
p. 145
|
artikel
|
| 8 |
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
|
Hoelzer, D.
|
|
|
35 |
1 |
p. 15-28
|
artikel
|
| 9 |
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?
|
Giordano, A.
|
|
|
35 |
1 |
p. 10-14
|
artikel
|
| 10 |
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial ☆
|
Cottereau, A.S.
|
|
|
35 |
1 |
p. 130-137
|
artikel
|
| 11 |
Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial
|
Chen, P.
|
|
|
35 |
1 |
p. 140-141
|
artikel
|
| 12 |
Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes
|
Thomas, A.
|
|
|
35 |
1 |
p. 7-9
|
artikel
|
| 13 |
POSing the question: MARIPOSA-2, do the ends justify the means?
|
Chen, M.F.
|
|
|
35 |
1 |
p. 4-6
|
artikel
|
| 14 |
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
|
Ladetto, M.
|
|
|
35 |
1 |
p. 118-129
|
artikel
|
| 15 |
Reply to the Letter to the Editor ‘There is no place for ovarian cancer screening in hereditary breast–ovarian cancer syndromes (in regard to “ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes”)’ by W. Tjalma
|
Sessa, C.
|
|
|
35 |
1 |
p. 139-140
|
artikel
|
| 16 |
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
|
Borghaei, H.
|
|
|
35 |
1 |
p. 66-76
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
35 |
1 |
p. i-ii
|
artikel
|
| 18 |
THANKS TO REFEREES 2023
|
|
|
|
35 |
1 |
p. 1-2
|
artikel
|
| 19 |
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma ☆
|
McGregor, B.A.
|
|
|
35 |
1 |
p. 91-97
|
artikel
|
| 20 |
There is no place for ovarian cancer screening in hereditary breast–ovarian cancer syndromes
|
Tjalma, W.A.A.
|
|
|
35 |
1 |
p. 138-139
|
artikel
|
| 21 |
VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC
|
Hochmair, M.J.
|
|
|
35 |
1 |
p. 142-144
|
artikel
|
Tijdschrift beschrijving